Toboroz
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
NCT07843498· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
NCT07473128· 3. fázis· Pharmacosmos A/S· Forrás
Toboroz
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test
2025-521045-24-00· 3. fázis· Unicancer· Forrás
Még nem toboroz
Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease
NCT07284394· 3. fázis· UNICANCER· Forrás
Toboroz
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
NCT07333066· 3. fázis· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Forrás
Még nem toboroz
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· 2. fázis· Federation Francophone de Cancerologie Digestive· Forrás
Toboroz
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· 2. fázis· UNICANCER· Forrás
Toboroz
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
NCT06471465· 3. fázis· Institut Cancerologie de l'Ouest· Forrás
Fut, nem toboroz
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485· 3. fázis· Celgene· Forrás
Toboroz
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· 2. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Toboroz
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990· 2/3. fázis· Bicara Therapeutics· Forrás
Toboroz
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
NCT06078384· 2. fázis· UNICANCER· Forrás
Toboroz
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)
NCT04262687· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás
Toboroz
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· 3. fázis· Amgen· Forrás
Toboroz
Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
NCT05346848· 2. fázis· Institut Bergonié· Forrás
Fut, nem toboroz
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence
NCT05297617· 2. fázis· Unicancer· Forrás
Toboroz
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· 3. fázis· ARCAGY/ GINECO GROUP· Forrás
Fut, nem toboroz
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX (GEMFOX)
NCT04167007· 2/3. fázis· Assistance Publique Hopitaux De Paris· Forrás
Fut, nem toboroz
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· 3. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás
Fut, nem toboroz
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
NCT02799706· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Lezárult
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
NCT02967289· 3. fázis· UNICANCER· Forrás
Lezárult
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
NCT01952223· 3. fázis· UNICANCER· Forrás